Currently, AbCellera Biologics Inc [ABCL] is trading at $3.68, up 2.51%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABCL shares have gain 6.36% over the last week, with a monthly amount drifted -5.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AbCellera Biologics Inc [NASDAQ: ABCL] stock has seen the most recent analyst activity on November 07, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $4 for it. On August 20, 2024, downgrade downgraded it’s rating to Hold. The Benchmark Company upgraded its rating to a Buy but stick to its price target of $9 on February 22, 2024. KeyBanc Capital Markets initiated its recommendation with an Overweight and recommended $6 as its price target on December 05, 2023. The Benchmark Company downgraded its rating to Hold for this stock on November 06, 2023.
This stock has fluctuated between a low of $1.89 and a high of $6.51 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $20.17 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $3.68 at the most recent close of the market. An investor can expect a potential return of 448.1% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
Trailing Twelve Months sales for AbCellera Biologics Inc [NASDAQ:ABCL] were 35.32M which represents 37.62% growth. Gross Profit Margin for this corporation currently stands at -1.05% with Operating Profit Margin at -8.6%, Pretax Profit Margin comes in at -5.8%, and Net Profit Margin reading is -4.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.17 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.55 points at the first support level, and at 3.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.77, and for the 2nd resistance point, it is at 3.85.
Ratios To Look Out For
To put it in perspective, the Current Ratio for AbCellera Biologics Inc [NASDAQ:ABCL] is 10.10. On the other hand, the Quick Ratio is 10.10, and the Cash Ratio is 1.21. Considering the valuation of this stock, the price to sales ratio is 31.19, the price to book ratio is 1.14.
